RPRX Royalty Pharma plc - Class A Ordinary Shares

NAS · US · Healthcare · Biotechnology · royaltypharma.com

56.82USD-0.59%Mkt Cap: 33.03B $P/E: 30.73Today

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed th…

Industry Peers

Biotechnology

Screen all

VRTX

Vertex Pharmaceuticals Incorporated - Common Stock

$127.85BUSDP/E 29.4

MRNA

Moderna, Inc. - Common Stock

$75.86BUSD

REGN

Regeneron Pharmaceuticals, Inc. - Common Stock

$75.69BUSDP/E 18.2

ARGX

argenx SE - American Depositary Shares

Revolution Medicines, Inc. - Common Stock

BeOne Medicines Ltd. - American Depositary Shares

$40.51BUSDP/E 63.9

ALNY

Alnylam Pharmaceuticals, Inc. - Common Stock

$29.40BUSDP/E 38.3

ROIV

Roivant Sciences Ltd. - Common Shares

$25.80BUSD

BNTX

BioNTech SE - American Depositary Shares

$24.34BUSD

INSM

Insmed Incorporated - Common Stock

$24.27BUSD

INCY

Incyte Corporation - Common Stock

Genmab A/S - American Depositary Shares

$21.69BUSDP/E 27.4

JAZZ

Jazz Pharmaceuticals plc - Ordinary Shares

$15.30BUSDP/E 16.1

ASND

Ascendis Pharma A/S - Ordinary Share

$14.99BUSDP/E 17.8

EXEL

Exelixis, Inc. - Common Stock

$14.47BUSDP/E 18.4

SMMT

Summit Therapeutics Inc. - Common Stock

$13.37BUSD

BBIO

BridgeBio Pharma, Inc. - Common Stock

$13.15BUSD

Key Statistics

Company

Market Cap33.03B USD

Enterprise Value36.53B USD

Revenue (TTM)2.54B USD

Gross Profit2.43B USD

Net Income (TTM)770.95M USD

Revenue/Share5.82 USD

Last Price56.82 USD

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees100

CountryUS

SectorHealthcare

IndustryBiotechnology

ISIN—

Valuation

P/E (Trailing)30.73

P/E (Forward)9.97

PEG1.33

EV/EBITDA23.46

EV/Revenue14.40

P/S13.02

P/B3.68

EPS (TTM)1.88

EPS (Forward)5.73

52W Range

34.6375% of range64.38

52W High64.38 USD

52W Low34.63 USD

Profitability

Gross Margin95.82%

Oper. Margin19.75%

EBITDA Margin61.41%

Profit Margin32.42%

ROE11.90%

ROA3.93%

Growth

Revenue Growth16.50%

Earnings Growth-46.30%

Cash Flow & Leverage

Operating CF2.49B USD

CapEx (TTM)—

FCF Margin-47.14%

FCF Yield-3.62%

Net Debt8.12B USD

Net Debt/EBITDA5.22

Balance Sheet

Debt/Equity1.38

Current Ratio2.80

Quick Ratio2.79

Book Value/Sh15.53 USD

Cash/Share1.88 USD

Dividends

Fwd Div Rate0.94 USD

Trail. Div Rate0.91 USD

Div. Yield1.64%

5Y Avg Yield2.17%

Payout Ratio48.40%

Ex-Div DateAug 14, 2026

Pay DateSep 10, 2026

Analyst Consensus

Rating—

Target (Mean)65.13 USD

Upside (mean)+14.6%

Target Range61.00 USD – 70.00 USD

61.00+14.6% to mean70.00

# Analysts8

Ownership

Shares Out.445.28M

Float417.57M

Insiders6.49%

Institutions87.32%

Short Interest

Short Ratio3.9d

Short % Float2.65%

Short % Out.2.62%

Shares Short11.65M

Short (prev mo.)11.61M

Technical

SMA 5059.42 (-4.4%)

SMA 20051.08 (+11.2%)

Beta0.43

S&P 52W Chg14.58%

Avg Vol (30d)2.98M

Avg Vol (10d)2.65M

Technical Indicators

RSI (14)38.5

MACD-0.5046

MACD Signal-0.2284

MACD Hist.-0.2762

BB Upper63.79 USD

BB Middle59.51 USD

BB Lower55.23 USD

BB Width14.38%

ATR (14)1.310 USD

Vol Ratio (20d)0.68x